

CLAIMS

1. A composition for ophthalmic use, comprising:
 - a) polyvinyl alcohol;
 - b) polyvinyl acetate;
 - c) a hydrophilic polymer; and
 - d) a phospholipid.
2. The composition of claim 1 wherein said phospholipid is formulated in polysorbate-80, glycerin, ethanol, and water.
3. The composition of claim 2 wherein said phospholipid is lecithin.
4. The composition of claim 1 further comprising water, one or more electrolytes to contribute to the well-being of the corneal epithelium, one or more preservatives, and one or more buffers.
5. The composition of claim 3 wherein said hydrophilic polymer is polyvinyl pyrrolidone.
6. The composition of claim 5 wherein the concentration of said polyvinyl alcohol is from about 0.5% to 10% by weight in water, said polyvinyl alcohol being about 96% to 99% hydrolyzed; the concentration of said polyvinyl acetate is from about 0.5% to 10% by weight in water, said polyvinyl acetate being about 73% to 93% hydrolyzed; the concentration of said polyvinyl pyrrolidone is from about 0.5% to 10% by weight in water; and the concentration of said phospholipid is from about 0.003% to 0.02% by weight in water.
7. The composition of claim 6 wherein said phospholipid is in the form of Amisol® Clear in a concentration from about 0.02% to 0.3% by weight in water.
8. An artificial tear film over the surface of an eye, comprising:
 - a) a first layer in direct contact with the ocular surface;
 - b) an aqueous layer over said first layer; and

- c) a layer of a simple phospholipid over said aqueous layer.
9. The artificial tear film according to claim 8 wherein said first layer comprises a phospholipid, said aqueous layer comprises polyvinyl alcohol, polyvinyl acetate, and polyvinyl pyrrolidone.
 10. The artificial tear film according to claim 9 wherein said phospholipid is formulated in polysorbate-80, glycerin, ethanol, and water.
 11. The artificial tear film according to claim 10 wherein said phospholipid is lecithin.
 12. The artificial tear film according to claim 9 further comprising water, one or more electrolytes to contribute to the well-being of the corneal epithelium, one or more preservatives, and one or more buffers.
 13. The artificial tear film according to claim 11 wherein the concentration of said polyvinyl alcohol is from about 0.5% to 10% by weight in water, said polyvinyl alcohol being about 96% to 99% hydrolyzed; the concentration of said polyvinyl acetate is from about 0.5% to 10% by weight in water, said polyvinyl acetate being about 73% to 93% hydrolyzed; the concentration of said polyvinyl pyrrolidone is from about 0.5% to 10% by weight in water; and the concentration of said phospholipid is from about 0.003% to 0.02% by weight in water.
 14. The artificial tear film according to claim 13 wherein said phospholipid is in the form of Amisol® Clear in a concentration from about 0.02% to 0.3% by weight in water.
 15. A method of formulating the composition of claim 1, comprising the steps of:
 - 1) forming a first aliquot in water by combining a hydrophilic polymer and a phospholipid and adjusting pH between 6.6 to 7.0;
 - 2) forming a second aliquot in water by combining polyvinyl alcohol and polyvinyl acetate, heating and stirring until dissolved, and adjusting pH between 6.6 to 7.0; and
 - 3) mixing said first aliquot with said second aliquot.
 16. The method of formulating the composition of claim 15 wherein said hydrophilic

polymer is polyvinyl pyrrolidone and said phospholipid is formulated in polysorbate-80, glycerin, ethanol, and water.

17. The method of formulating the composition of claim 16 wherein said phospholipid is in the form of Amisol® Clear.
18. The method of formulating the composition of claim 17 wherein one or more electrolytes to contribute to the well-being of the corneal epithelium, one or more preservatives, and one or more buffers are added to said first aliquot.
19. A method of treating dry eye syndrome comprising applying the composition of claim 1 topically to the eye daily as frequently as desired sufficient to cover the surface of the conjunctiva or cornea .
20. A method of rewetting contact lens in the eye comprising applying the composition of claim 1 topically to the eye daily as frequently as desired sufficient to cover the contact lens.
21. A method of delivering one or more pharmacologic agents for the topical treatment of the eye comprising adding said pharmacologic agents to an ophthalmic composition and applying said composition to the eye according to claim 19, wherein said composition comprises polyvinyl alcohol, polyvinyl acetate, a hydrophilic polymer, and a phospholipid.